Specialty code 1835P0018X · Santa Rosa, CA
NPI
1891243366
Since 2016
Specialty
Specialty code 1835P0018X
Code 1835P0018X
Group practices
0
Medicare group memberships
Hospitals
0
Hospital affiliations
401 Bicentennial Way
Santa Rosa, CA, 95403
Phone (707) 393-4119
Medicare paid
-
No Medicare services published
Medicare patients
-
Drug cost, 2024
$425K
2,690 prescriptions
Company payments
-
None reported
Medicare prescription drug claims, 2024
In 2024, the drug Sam Zakkour prescribed most often to Medicare patients was Atorvastatin Calcium, with 530 prescriptions and refills. In total Sam Zakkour wrote 2,690 Medicare prescriptions that cost $425K.
| Drug |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2021-12-22.
| Claims |
|---|
| 30-day fills |
|---|
| Patients |
|---|
| Cost |
|---|
| Atorvastatin Calcium Generic | 530 | 1,764 | 246 | $6,779 |
| Metformin Hcl Er Metformin Hcl | 202 | 664 | 112 | $2,030 |
| Jardiance Empagliflozin | 191 | 616 | 99 | $109K |
| Metformin Hcl Generic | 177 | 587 | 76 | $2,211 |
| Glipizide Generic | 150 | 490 | 71 | $1,735 |
| Insulin Glargine-Yfgn Generic | 128 | 377 | 67 | $18K |
| Ozempic Semaglutide | 124 | 126 | 33 | $93K |
| Humulin N Insulin Nph Human Isophane | 97 | 287 | 60 | $18K |
| Rosuvastatin Calcium Generic | 91 | 303 | 46 | $1,055 |
| Ultra-Fine Nano Pen Needle Pen Needle, Diabetic | 86 | 230 | 47 | $2,219 |
| Victoza 2-Pak Liraglutide | 79 | 84 | 30 | $51K |
| Lisinopril Generic | 72 | 240 | 40 | $877 |
| Veo Insulin Syringe Syringe-Needle,insulin,0.5 Ml | 68 | 203 | 38 | $1,816 |
| Alendronate Sodium Generic | 65 | 182 | 38 | $637 |
| Pioglitazone Hcl Generic | 50 | 167 | 25 | $610 |
Brand drugs: 887 claims; generic drugs: 1,570 claims.
Money and other things of value reported by the companies
No payments from drug or medical device companies to Sam Zakkour were reported in the years we have.
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.